(R)-PR-924

(R)-PR-924

• UNSPSC Description: (R)-PR-924 is the isomer of PR-924 (HY-123587), and can be used as an experimental control. PR-924 is a selective tripeptide epoxyketone immunoproteasome subunit LMP-7 inhibitor with an IC50 of 22 nM. PR-924 covalently modifies proteasomal N-terminal threonine active sites. PR-924 inhibits growth and triggers apoptosis in multiple myeloma (MM) cells. PR-924 has antitumor activities[1][2].
• Target Antigen: Apoptosis
• Type: Reference compound
• Related Pathways: Apoptosis
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/r-pr-924.html
• Purity: 98.50
• Solubility: DMSO : 125 mg/mL (ultrasonic)
• Smiles: O=C(N[C@@H](CC1=CC=CC=C1)C([C@]2(CO2)C)=O)[C@H](NC([C@@H](C)NC(C(CC3=CC=CC=C43)=C4C)=O)=O)CC5=CNC6=CC=CC=C56
• Molecular Weight: 618.72
• References & Citations: [1]Singh AV, et al. PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo. Br J Haematol. 2011 Jan;152(2):155-63.|[2]Parlati F, et al. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood. 2009 Oct 15;114(16):3439-47.
• Shipping Conditions: Room Temperature
• Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
• Clinical Information: No Development Reported